What is Synlogic?
Synlogic is at the forefront of bringing the transformative potential of synthetic biology to medicine. Leveraging a premiere, reproducible, and modular microbial engineering platform, Synlogic designs Synthetic Biotic medicines aimed at treating diseases by targeting validated underlying biology. The company's proprietary pipeline focuses on metabolic disorders such as phenylketonuria (PKU), enteric hyperoxaluria, and homocystinuria, while also building a portfolio of partner-able assets in immunology. This strategic focus positions Synlogic to address significant unmet medical needs through groundbreaking therapeutic modalities.
How much funding has Synlogic raised?
Synlogic has raised a total of $283.9M across 6 funding rounds:
Series A
$34.4M
Series B
$40M
Series C
$42M
Stock Offering
$57.5M
Stock Offering
$30M
Corporate Investment
$80M
Series A (2014): $34.4M with participation from Bill & Melinda Gates Foundation, Atlas Ventures, and NEA
Series B (2016): $40M led by Atlas Ventures, NEA, OrbiMed, and Deerfield Management Company
Series C (2017): $42M supported by CLI Ventures, Rock Springs Capital, Deerfield, Perceptive Advisors, Atlas Ventures, OrbiMed, Ally Bridge Group, Arctic Aurora LifeScience, Aju IB Investment, and NEA
Stock Issuance/Offering (2018): $57.5M featuring Undisclosed
Stock Issuance/Offering (2018): $30M backed by Undisclosed
Corporate Investment (2019): $80M with participation from Ginkgo Bioworks
Key Investors in Synlogic
Ginkgo Bioworks
Ginkgo Bioworks is a biotechnology company developing a horizontal platform for cell programming, used on behalf of their customers. They are headquartered in Boston, Massachusetts.
Atlas Ventures
Atlas Venture is an early-stage venture capital firm focused on creating and building breakthrough biotechnology companies that translate cutting-edge science into life-changing medicines. They partner with entrepreneurs to support the launch and growth of innovative biotech startups.
NEA
NEA (New Enterprise Associates) is a global venture capital firm that invests in companies across various stages and sectors, with a significant focus on healthcare and technology. They are known for supporting transformative companies from inception through growth.
What's next for Synlogic?
With substantial enterprise-level backing and a recent strategic investment, Synlogic is well-positioned for accelerated growth and the advancement of its pipeline. The company's focus on synthetic biology for therapeutic development suggests a trajectory towards clinical trials and potential commercialization of its novel Synthetic Biotic medicines. Future endeavors will likely involve expanding its portfolio, forging strategic partnerships, and further validating its platform's efficacy in treating complex diseases, particularly in metabolic and immunological indications.
See full Synlogic company page
